Secukinumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | IL17A |
| Clinical data | |
| Trade names | Cosentyx |
| Other names | AIN457 |
| AHFS/Drugs.com | cosentyx |
| License data | |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number |
|
| DrugBank | |
| ChemSpider |
|
| KEGG | |
| Chemical and physical data | |
| Formula | C6584H10134N1754O2042S44 |
| Molar mass | 147.94 kg/mol g·mol−1 |
  (what is this?) (verify) | |
Secukinumab, trade name Cosentyx, is a human IgG1κ monoclonal antibody that binds to the protein interleukin (IL)-17A, and is marketed by Novartis for the treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis.[1][2]
It inhibits a member of the cytokine family, interleukin 17A.[1]
Medical uses
It is used to treat psoriasis, ankylosing spondylitis, and psoriatic arthritis.[1][2][3] It is given by subcutaneous injection and is sold in a pre-filled syringe or autoinjector that can be used at home and as a lyophilized powder for use in hospitals and clinics.[2]
Secukinumab was not tested in pregnant women; animal studies did not show harm at relevant doses. The FDA advises that the drug should be used in pregnant women only if the risk to the fetus justifies the potential benefit;[2] the EMA advises that women should not become pregnant while taking it.[1]
It should not be given to people with active infections since it is suppresses the immune system.[1]
Adverse effects
Very common (greater than 10% of people experience them) adverse effects include upper respiratory tract infections [1]
Common (between 1% and 10% of people experience them) include oral herpes, runny nose, and diarrhea.[1]
In clinical trials there were rare instances of hypersensitivity reactions, severe infections, and some cases of serious inflammatory bowel disease, some of which were new and some of which were exacerbations of existing conditions.[2]
Pharmacology
It inhibits a member of the cytokine family, interleukin 17A, which is produced mainly by inflammatory T helper 17 cells.[4] IL17A is upregulated in serum of people with psoriasis and in the synovial fluid of people with psoriatic arthritis, and promotes inflammation when it binds to the interleukin-17 receptor which is expressed in various types of cells, including keratinocytes in skin.[4][5]
It is mostly eliminated by being taken up into cells via endocytosis and being broken down inside them.[1]
Chemistry
Secukinumab is a recombinant fully human IgG1/kappa monoclonal antibody and is manufactured in chinese hamster ovary cells.[1]
History
Secukinumab was discovered and developed by Novartis using developmental name AIN457, and the first publication was a Phase I trial published in 2010.[6][7][8][9]
In January 2015, the FDA approved secukinumab to treat adults with moderate-to-severe plaque psoriasis.[10] It was the first IL17A inhibiting drug ever approved.[5] In January 2016, the FDA approved it to treat adults with ankylosing spondylitis, and psoriatic arthritis.[11]
References
- ^ a b c d e f g h i "Cosentyx 150 mg solution for injection in pre-filled syringe and pre-filled pen - Summary of Product Characteristics". UK Electronic Medicines Compendium. 15 August 2017. Retrieved 2 October 2017.
- ^ a b c d e "Cosentyx (secukinumab) injection" (PDF). FDA. September 2017. For label updates see FDA index page for BLA 125504
- ^ Patel, NU; Vera, NC; Shealy, ER; Wetzel, M; Feldman, SR (28 August 2017). "A Review of the Use of Secukinumab for Psoriatic Arthritis". Rheumatology and therapy. doi:10.1007/s40744-017-0076-0. PMID 28849401.
- ^ a b Lubrano, E; Perrotta, FM (2016). "Secukinumab for ankylosing spondylitis and psoriatic arthritis". Therapeutics and clinical risk management. 12: 1587–1592. doi:10.2147/TCRM.S100091. PMC 5085310. PMID 27799780.
{{cite journal}}: CS1 maint: unflagged free DOI (link) - ^ a b Shirley, M; Scott, LJ (July 2016). "Secukinumab: A Review in Psoriatic Arthritis". Drugs. 76 (11): 1135–45. doi:10.1007/s40265-016-0602-3. PMID 27299434.
- ^ Nelson, AL; Dhimolea, E; Reichert, JM (October 2010). "Development trends for human monoclonal antibody therapeutics". Nature reviews. Drug discovery. 9 (10): 767–74. doi:10.1038/nrd3229. PMID 20811384.
- ^ Hueber, W; Patel, DD; Dryja, T; Wright, AM; Koroleva, I; Bruin, G; Antoni, C; Draelos, Z; Gold, MH; Psoriasis Study, Group.; Durez, P; Tak, PP; Gomez-Reino, JJ; Rheumatoid Arthritis Study, Group.; Foster, CS; Kim, RY; Samson, CM; Falk, NS; Chu, DS; Callanan, D; Nguyen, QD; Uveitis Study, Group.; Rose, K; Haider, A; Di Padova, F (6 October 2010). "Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis". Science translational medicine. 2 (52): 52ra72. doi:10.1126/scitranslmed.3001107. PMID 20926833.
- ^ "Novartis Snags Remaining 23% Stake in Alcon with $12.9B Cash and Share Deal". Genetic Engineering News. December 15, 2010.
- ^ Padova, Franco E. Di; Gram, Hermann; Hofstetter, Hans; Jeschke, Margit; Rondeau, Jean-Michel; Berg, Wim Van Den (2010). "US 7807155: IL-17 antagonistic antibodies".
- ^ "FDA approves new psoriasis drug Cosentyx" (Press release). United States Food and Drug Administration. January 21, 2015. Retrieved January 21, 2015.
- ^ "Press release: Novartis receives two new FDA approvals for Cosentyx to treat patients with ankylosing spondylitis and psoriatic arthritis in the US". Novartis. 2016-01-15.